Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer and weight-loss therapy.

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

People may start to regain weight within weeks of discontinuing weight loss drugs, study finds - Study finds significant ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes. At the 15mg dose · Clinical Trials Arena. GlobalData . Thu, Nov 14, 2024, 5:29 AM 2 min read. In This Article: ...

Source: Analyst estimates for the quarter provided by FactSet.